| Market Cap | $150.34M+28.1% |
| Revenue (ttm) | n/a |
| Net Income | -$85.03M |
| EPS | -$0.73 |
| Shares Out | 84.46M |
| PE Ratio | n/a |
| Forward PE | -2.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,292,761 |
| Open | $1.87 |
| Previous Close | $1.90 |
| Day's Range | $1.76 - $2.00 |
| 52-Week Range | $1.39 - $4.49 |
| Beta | 0.96 |
| Analysts | Strong Buy |
| Price Target | $9.00(+405.62%) |
| Earnings Date | Nov 13, 2026 |
About ELDN
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
$ELDN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ELDN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ELDN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ELDN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ELDN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ELDN from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from ELDN’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| IWC | iShares Micro-Cap ETF | 0.05% |
Weight is the stock’s share of each fund’s holdings.
